E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Congenital adrenal hyperplasia (CAH) is a group of rare inherited endocrine disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. |
L'iperplasia surrenalica congenita (CAH) è un gruppo di malattie endocrine ereditarie rare caratterizzate da una carenza di uno degli enzimi necessari per produrre ormoni specifici. |
|
E.1.1.1 | Medical condition in easily understood language |
Classic Congenital Adrenal Hyperplasia (CAH) |
Iperplasia surrenale congenita classica (CAH) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010323 |
E.1.2 | Term | Congenital adrenal hyperplasia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the efficacy of crinecerfont, compared with placebo, in reducing adrenal steroid levels during a glucocorticoid-stable period. • To evaluate the efficacy of crinecerfont, compared with placebo, in reducing daily glucocorticoid dosage while maintaining adrenal androgen control. • To evaluate the effect of crinecerfont, compared with placebo, on clinical endpoints associated with supraphysiologic glucocorticoid dosing and androgen excess. • To evaluate plasma concentrations of crinecerfont and metabolites. • To assess the safety and tolerability of crinecerfont. |
• Valutare l’efficacia di crinecerfont rispetto a placebo in termini di riduzione dei livelli di steroidi surrenalici durante un periodo stabile di assunzione di glucocorticoidi. • Valutare l’efficacia di crinecerfont rispetto a placebo in termini di riduzione della dose giornaliera di glucocorticoidi, pur mantenendo il controllo della produzione di androgeni surrenalici. • Valutare l’effetto di crinecerfont rispetto a placebo su endpoint clinici associati alla somministrazione di dosi sovrafisiologiche di glucocorticoidi e all’eccesso di androgeni. • Valutare le concentrazioni plasmatiche di crinecerfont e dei suoi metaboliti • Valutare la sicurezza e la tollerabilità di crinecerfont. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit. - Be a female or male 2 to 17 years of age with a body weight of at least 10 kg. - Have a medically confirmed diagnosis of classic CAH due to 21- hydroxylase deficiency. - Be on a stable regimen of glucocorticoid treatment for CAH. - Have elevated adrenal androgens. - If treated with fludrocortisone, be on a stable regimen with plasma renin activity (PRA) indicating adequate replacement. |
- Essere disposti e capaci di aderire alle procedure di studio, incluse le esigenze al centro e tornare per la visita di follow-up - Essere femmine o maschi di età compresa tra 2 e 17 anni con un peso corporeo di almeno 10 kg. - Presentare una diagnosi confermata a livello medico di CAH classica dovuta a deficit di 21-idrossilasi - Essere in un regime di dosaggio di trattamento stabile di glucocorticoidi per la CAH - Presentare alti livelli di androgeni surrenalici - Se trattati con fludrocortisone, essere in un regime stabile con attività di renina plasmatica (PRA) che indica una sostituzione adeguata. |
|
E.4 | Principal exclusion criteria |
- Have a diagnosis of any of the other forms of classic CAH. - Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic daily therapy with oral glucocorticoids. - Have a clinically significant unstable medical condition or chronic disease other than CAH - Have a history of malignancy, unless successfully treated with curative intent and considered to be cured. - Have a known history of clinically significant arrhythmia or abnormalities on screening ECG. - Have a known hypersensitivity or allergy to any corticotropin-releasing hormone (CRH) receptor antagonist. - Females who are pregnant or lactating. |
- Avere una diagnosi di qualsiasi altra forma di CAH classica - Presentare un’anamnesi di surrenectomia bilaterale, ipopituitarismo, o altra condizione che richiede una terapia quotidiana cronica con glucocorticoidi orali. - Avere una condizione medica instabile clinicamente significativa o malattia cronica diversa dalla CAH - Presentare un’anamnesi di neoplasia maligna, a meno che non sia trattata con successo con intento curativo e sia considerata curata. - Presentare un’anamnesi nota di aritmia cardiaca clinicamente rilevante o anomalie evidenziate dall’ECG allo screening - Presentare una ipersensibilità nota o allergia a qualsiasi antagonista del recettore dell’ormone di rilascio della corticotropina (CRH). - Soggetti di sesso femminile in gravidanza o in allattamento. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in serum androstenedione at Week 4. |
Cambiamento rispetto al basale dell’androstenedione sierico alla Settimana 4 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Percent change from baseline in glucocorticoid dose at Week 28 - Change from baseline in serum 17-hydroxyprogesterone at Week 4 |
- Cambiamento percentuale rispetto al basale della dose dei glucocorticoidi alla Settimana 28 - Cambiamento rispetto al basale del 17-idrossiprogesterone sierico alla Settimana 4 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Week 4 and Week 28 |
Settimana 4, Settimana 28 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
periodo in aperto |
open-label period |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 21 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
United States |
Belgium |
France |
Germany |
Italy |
Poland |
Spain |
Sweden |
Greece |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |